CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

Source link

Related posts

Study: Too Many IBD Patients Treated Inappropriately


Sodium consumption increases GI bloating


Purdue Pharma tentatively settles opioid lawsuits, others still pending


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy